10-K: Nutriband Inc. Reports Increased R&D Spending and Net Loss in Fiscal Year 2025 Amid AVERSA Fentanyl Development

Nutriband Inc.'s 10-K filing reveals a widened net loss for fiscal year 2025, driven by increased research and development expenses for its AVERSA Fentanyl product and an impairment charge, despite a slight revenue increase.

Summary

• Nutriband Inc., a company focused on developing transdermal pharmaceutical products, reported its Form 10-K for the fiscal year ended January 31, 2025.
• The company's primary focus is the development of AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system.
• Revenues increased slightly to $2,139,537 in 2025 from $2,085,314 in 2024, primarily from the Pocono Pharmaceuticals segment.
• The company's net loss widened to $10,482,617, or $(0.99) per share, compared to a loss of $5,485,314, or $(0.69) per share in the previous year.
• Research and development expenses for AVERSA Fentanyl increased to $3,119,134 in 2025 from $1,960,425 in 2024.
• The company recorded an impairment charge of $3,595,216 related to Goodwill and intangible assets.
• As of January 31, 2025, Nutriband had $4,311,719 in cash and cash equivalents and working capital of $3,811,420.
• The company completed an $8,400,000 equity financing in April 2024.
• Nutriband is involved in a lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP, with the company denying all allegations and initiating counterclaims.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased slightly and the company secured financing, the widened net loss and impairment charge raise concerns. The ongoing lawsuit adds further uncertainty.

Positives

• Revenue increased slightly to $2,139,537 in 2025 from $2,085,314 in 2024.
• The company completed an $8,400,000 equity financing in April 2024, strengthening its financial position.
• The company is actively developing AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system, which could address a significant market need.
• The company has cash and cash equivalents of $4,311,719 and working capital of $3,811,420 as of January 31, 2025.

Negatives

• The company's net loss widened to $10,482,617 in 2025 from $5,485,314 in 2024.
• The company recorded an impairment charge of $3,595,216 related to Goodwill and intangible assets.
• The company is involved in a lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP.
• The company's disclosure controls and internal controls over financial reporting were not effective as of January 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate sufficient funds from operations and raise additional capital.
• The company's success is dependent on the successful development, regulatory approval, and commercialization of AVERSA Fentanyl.
• The company faces significant competition from better-known and better-capitalized companies.
• Healthcare reforms and related reductions in pharmaceutical pricing may adversely affect the company's business.
• The company may not be successful in identifying acquisition targets or integrating their businesses with its existing business.
• The company is dependent on key personnel, and the loss of these individuals could materially impair its ability to conduct its business.
• The company's lack of internal controls over financial reporting may affect the market for and price of its common stock.

Future Outlook

The company plans to continue developing its AVERSA abuse deterrent transdermal patch products, with a focus on AVERSA Fentanyl, AVERSA Buprenorphine, and AVERSA Methylphenidate. The company expects an increase in demand in the subsequent year for the Pocono Pharmaceuticals segment.

Industry Context

The company operates in the competitive pharmaceutical industry, focusing on abuse-deterrent technologies to address the opioid crisis. The company's AVERSA technology aims to reduce the abuse and misuse of fentanyl and other drugs with abuse potential.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document mentions that the company is not aware of any abuse deterrent transdermal products that are in development or being marketed at this time.
• The document mentions that the company will compete with currently marketed products that do not contain abuse deterrent features as well as other products that may employ different abuse deterrent technology.

Legal Proceedings

• The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (Gunnar) and Lucosky Brookman LLP (LB) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023.
• The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Companys termination of an engagement letter for assistance with a public stock offering.
• Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.
• The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination.

Related Party Transactions

• On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors which included two related parties.
• During the year ending January 31, 2025, the Company received $300,000 from the credit line facility with TII Jet Services LDA.
• On May 15, 2024, the Company converted the debt and accrued interest into 76,230 shares of common stock and issued 152,460 warrants to the lender.

Stakeholder Impact

• Shareholders: Dilution from equity financing, potential for future profitability dependent on product development and regulatory approval.
• Employees: Continued employment dependent on company's financial performance and product development success.
• Customers: Potential for new abuse-deterrent transdermal products to address unmet needs.
• Suppliers: Continued business relationship dependent on company's financial performance and product development success.
• Creditors: Repayment of debt dependent on company's financial performance and ability to generate cash flow.

Next Steps

• Continue research and development of AVERSA Fentanyl and other abuse-deterrent transdermal products.
• Pursue regulatory approval for AVERSA Fentanyl.
• Negotiate a commercial supply agreement with Kindeva Drug Delivery.
• Address the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

AVERSA Fentanyl, transdermal, Nutriband, pharmaceutical, abuse deterrent, Kindeva, FDA, clinical trials, financial results, Pocono Pharmaceuticals